In a report released yesterday, Rajesh Kumar from HSBC upgraded Roche Holding AG to a Buy, with a price target of CHF320.00. The company’s shares closed yesterday at $353.22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Kumar is a 4-star analyst with an average return of 14.5% and a 59.76% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Roche Holding.
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $348.01, implying a -1.48% downside from current levels. In a report released on September 26, Kepler Capital also maintained a Buy rating on the stock with a CHF315.00 price target.
The company has a one-year high of $358.64 and a one-year low of $269.80. Currently, Roche Holding AG has an average volume of 9,160.
Read More on RHHVF:
Disclaimer & DisclosureReport an Issue
- Roche upgraded to Buy from Hold at HSBC (yesterday)
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- White House announces deal with Pfizer for ‘most-favored-nation pricing’
- Trump says other drugmakers to join Pfizer with ‘most favored nation’ prices
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
